Heiring Christian, Poorisrisak Porntiva, Breindahl Niklas, Zachariassen Gitte, Eckardt Maria-Christina, Viuff Anne-Cathrine, Bender Lars, Agergaard Peter, Aunsholt Lise, Brink Henriksen Tine
Department of Neonatal and Paediatric Intensive Care, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Acta Paediatr. 2025 Oct;114(10):2535-2542. doi: 10.1111/apa.70128. Epub 2025 May 10.
To validate a prototype point-of-care (POC) test for the lecithin/sphingomyelin (L/S) ratio by identifying the optimal L/S cut-off for predicting surfactant need in preterm infants < 30 weeks' gestation using gastric aspirates (GAS) sampled at birth and to assess clinical feasibility.
GAS was sampled within 45 min of birth and analysed using the only available prototype POC L/S test. The primary outcome was the optimal L/S cut-off and diagnostic accuracy in predicting rescue surfactant treatment per European RDS guidelines, assessed by receiver operating characteristics. L/S results were blinded to clinicians. Due to a dispute between clinical investigators and patent holders, legal restrictions prohibit reporting of the primary outcome.
Of 93 eligible infants, 25 were not included: Six cases (6%) had no GAS available, 12 infants (13%) received surfactant before sampling and 7 (8%) other reasons. Of 68 included, 42 (62%) received surfactant, and 40% were treated within 2 h of life (median: 147 min [IQR: 89; 327]).
We aimed to validate a POC L/S test but are legally restricted from disclosing results. Clinical applicability seems limited, as a substantial proportion of infants had no GAS available or required surfactant before sampling. The potential to accelerate treatment appears limited.
通过确定使用出生时采集的胃吸出物(GAS)预测孕周<30周早产儿表面活性剂需求的最佳卵磷脂/鞘磷脂(L/S)比值临界值,验证一种用于L/S比值的即时检验(POC)原型,并评估其临床可行性。
在出生后45分钟内采集GAS,并使用唯一可用的POC L/S检验原型进行分析。主要结局是根据欧洲RDS指南预测抢救性表面活性剂治疗的最佳L/S临界值和诊断准确性,通过受试者工作特征曲线进行评估。L/S结果对临床医生保密。由于临床研究人员与专利持有人之间的纠纷,法律限制禁止报告主要结局。
93名符合条件的婴儿中,25名未纳入:6例(6%)没有可用的GAS,12名婴儿(13%)在采样前接受了表面活性剂治疗,7例(8%)因其他原因。在纳入的68例中,42例(62%)接受了表面活性剂治疗,40%在出生后2小时内接受治疗(中位数:147分钟[四分位间距:89;327])。
我们旨在验证一种POC L/S检验,但因法律限制无法公布结果。临床适用性似乎有限,因为相当一部分婴儿没有可用的GAS或在采样前需要表面活性剂。加速治疗的潜力似乎有限。